After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial. Tanezumab is a nerve growth factor (NGF ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.

Merck & Co., Inc. (NYSE:MRK) announced that a phase III study evaluating its blockbuster PD-L1 inhibitor, Keytruda in patients... Investors in Pfizer Inc. (NYSE:PFE) need to pay close attention to ...

2 Biomedical Institute for Pioneering Investigation via Convergence and Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, Beijing, China 3 Beijing Advanced Innovation ...

Abstract Background Patients with psoriatic arthritis (PsA) experience reduced physical function and impaired quality of life. Better patient-reported functional outcomes are found when lower disease ...

By Hannah Skentelbery on 17th March 2025 3:11 pm Health ...